WBIO:LSE:LSE-WisdomTree BioRevolution UCITS ETF - USD Acc GBP (GBX)

ETF | Others |

Last Closing

USD 1373.7

Change

0.00 (0.00)%

Market Cap

USD 3.60M

Volume

124.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-08-31 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R1O:LSE Amazon.com Inc.

N/A

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+0.14 (+0.12%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.12 (+0.64%)

USD 557.54B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.01 (+0.09%)

USD 496.18B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
0QZK:LSE Coca-Cola Co.

-0.45 (-0.63%)

USD 266.08B
0QZO:LSE 0QZO

+1.60 (+1.80%)

USD 258.54B
PRJU:LSE Amundi Index Solutions - Amund..

+0.21 (+0.69%)

USD 209.75B
0QZ3:LSE Qualcomm Inc.

+1.37 (+0.83%)

USD 202.26B
0R24:LSE Intel Corp.

+0.42 (+2.15%)

USD 196.14B

ETFs Containing WBIO:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -5.37% 12% F 25% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -5.37% 12% F 25% F
Trailing 12 Months  
Capital Gain -3.84% 14% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.84% 14% F 27% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain -6.14% N/A N/A 20% F
Dividend Return -6.14% N/A N/A 19% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 7.79% N/A N/A 86% B+
Risk Adjusted Return -78.80% N/A N/A 9% A-
Market Capitalization 3.60M 16% F 8% B-

Annual Financials (GBX)

Quarterly Financials (GBX)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.